Pharmacology of Sulfonamides and Cotrimoxazole

1. Introduction/Overview

Sulfonamides represent one of the earliest classes of synthetic antimicrobial agents, marking a pivotal advancement in chemotherapy. The discovery of prontosil in the 1930s initiated the era of effective antibacterial treatment for systemic infections. While their use as single agents has diminished due to resistance and the development of newer antibiotics, sulfonamides retain significant clinical utility, particularly in fixed-dose combination with trimethoprim as cotrimoxazole. This combination exploits sequential blockade of bacterial folate synthesis, resulting in synergistic antibacterial activity and a broader spectrum of action. The pharmacology of these agents encompasses unique mechanisms, distinct pharmacokinetic profiles, and a well-characterized spectrum of both therapeutic and adverse effects.

The clinical relevance of sulfonamides and cotrimoxazole remains substantial in modern therapeutics. They serve as first-line agents for specific infections, including Pneumocystis jirovecii pneumonia prophylaxis and treatment, nocardiosis, and urinary tract infections caused by susceptible organisms. Furthermore, they are employed in the management of toxoplasmosis, certain gastrointestinal infections, and as alternatives in patients with penicillin allergies for conditions like acute otitis media and exacerbations of chronic bronchitis. Understanding their pharmacology is essential for optimizing therapeutic outcomes and minimizing the risk of adverse reactions, which can be severe.

Learning Objectives

• Describe the chemical basis and classification of sulfonamide antimicrobials.
• Explain the molecular mechanism of action of sulfonamides as single agents and the synergistic mechanism of cotrimoxazole.
• Analyze the absorption, distribution, metabolism, and excretion (ADME) profiles of representative agents and their clinical implications.
• Identify the primary therapeutic indications, common adverse effects, and serious toxicities associated with sulfonamide and cotrimoxazole therapy.
• Apply knowledge of pharmacokinetics, drug interactions, and special population considerations to develop appropriate therapeutic regimens.

2. Classification

Sulfonamides can be classified according to their chemical structure, pharmacokinetic properties, and clinical duration of action. The fundamental chemical structure consists of a para-aminobenzenesulfonamide nucleus. Substitutions at the N¹ position influence antibacterial potency, protein binding, and pharmacokinetic behavior, while substitutions at the N⁴ position (the amino group) are typically responsible for prodrug characteristics.

Chemical and Pharmacokinetic Classification

• Oral, Absorbable Agents (Systemic):
  • Short-Acting (t_1/2 4-8 hours): Sulfisoxazole, sulfadiazine. These agents require frequent dosing (every 4-6 hours).
  • Intermediate-Acting (t_1/2 10-17 hours): Sulfamethoxazole. Commonly used in cotrimoxazole, allowing for twice-daily dosing.
  • Long-Acting (t_1/2 > 24 hours): Sulfadoxine. Used primarily in combination with pyrimethamine for malaria prophylaxis and treatment.
• Oral, Poorly Absorbed Agents (GI Tract):
  • Sulfasalazine: Used in inflammatory bowel disease and rheumatoid arthritis. It is cleaved by colonic bacteria into 5-aminosalicylic acid (5-ASA) and sulfapyridine.
  • Phthalylsulfathiazole, Succinylsulfathiazole: Largely historical, designed for local action within the bowel lumen.
• Topical Agents:
  • Sulfacetamide: Used in ophthalmic preparations for conjunctivitis and other superficial eye infections.
  • Mafenide and Silver Sulfadiazine: Used topically for burn wound prophylaxis against Pseudomonas aeruginosa and other gram-negative bacteria.
• Fixed-Dose Combination:
  • Cotrimoxazole (Trimethoprim-Sulfamethoxazole, TMP-SMX): This is a synergistic combination typically formulated in a 1:5 ratio (trimethoprim:sulfamethoxazole). The standard oral and intravenous formulation contains 80 mg TMP and 400 mg SMX, with double-strength tablets containing 160 mg TMP and 800 mg SMX.

3. Mechanism of Action

The antibacterial activity of sulfonamides is based on the principle of competitive antagonism. These agents are structural analogs of para-aminobenzoic acid (PABA), an essential substrate in the bacterial synthesis of folate. Trimethoprim targets a subsequent step in the same pathway, and their combination in cotrimoxazole creates a sequential, synergistic blockade.

Molecular and Cellular Mechanisms

Bacteria synthesize dihydrofolic acid de novo, a process absent in human cells, which obtain preformed folate from the diet. The initial step in bacterial folate synthesis involves the condensation of PABA with dihydropteroate pyrophosphate, catalyzed by the enzyme dihydropteroate synthase (DHPS). Sulfonamides, as PABA analogs, competitively inhibit DHPS. The inhibition constant (K_i) for sulfonamides is typically lower than the Michaelis constant (K_m) for PABA, meaning the enzyme has a higher affinity for the drug than for its natural substrate under therapeutic conditions. This competition prevents the formation of dihydropteroic acid, leading to a deficiency in dihydrofolic acid and its reduced derivative, tetrahydrofolic acid (THF). THF is a crucial cofactor in the synthesis of purines, pyrimidines, and some amino acids, ultimately inhibiting bacterial DNA, RNA, and protein synthesis.

The action of sulfonamides is bacteriostatic. Their effectiveness can be antagonized by the presence of excess PABA, as found in purulent tissue or necrotic material, which may explain therapeutic failures in such environments. Furthermore, pus and tissue breakdown products like thymidine can bypass the folate blockade, allowing bacteria to synthesize DNA via salvage pathways.

Mechanism of Cotrimoxazole (Sequential Double Blockade)

Trimethoprim is a diaminopyrimidine that inhibits bacterial dihydrofolate reductase (DHFR), the enzyme responsible for reducing dihydrofolic acid to tetrahydrofolic acid. This step occurs immediately downstream of the step inhibited by sulfonamides. When used in combination, the two agents produce a sequential, two-step blockade of the folate pathway.

The synergy observed with cotrimoxazole arises from several factors. First, it results in a complete shutdown of the pathway, making reversal by accumulated substrates (like dihydrofolic acid) less likely. Second, the combination is often bactericidal against many susceptible organisms, whereas each agent alone is typically bacteriostatic. Third, the development of resistance is less probable, as it would require simultaneous mutations in two distinct enzymes (DHPS and DHFR). The 1:5 ratio of TMP:SMX in the fixed-dose combination is designed to achieve plasma concentrations that approximate the optimal synergistic ratio, which is often around 1:20 for the inhibition of most susceptible pathogens, considering differences in protein binding and tissue penetration.

It is critical to note that trimethoprim has selective toxicity for bacterial DHFR, exhibiting approximately 50,000-100,000 times greater affinity for the bacterial enzyme compared to the mammalian enzyme. This selectivity is the basis for its safety margin in human use.

4. Pharmacokinetics

The pharmacokinetic properties of sulfonamides vary considerably among individual agents, influencing their dosing regimens and clinical applications. Sulfamethoxazole, as a component of cotrimoxazole, is the most clinically relevant systemic sulfonamide and will be discussed in detail alongside trimethoprim.

Absorption

Most systemic sulfonamides are well absorbed from the gastrointestinal tract, with bioavailability typically exceeding 90%. Absorption occurs primarily in the small intestine. The rate of absorption can be influenced by the formulation and the presence of food, though food generally does not significantly affect the total extent of absorption. Sulfasalazine is an exception; it is poorly absorbed and reaches the colon intact, where bacterial azoreductases cleave it into its active components. Topical agents like silver sulfadiazine and mafenide act locally, with systemic absorption being variable and more significant in the case of extensive burn wounds, particularly for mafenide, which can cause metabolic acidosis.

Distribution

Sulfonamides are widely distributed throughout body fluids and tissues. They readily cross the placenta and enter the fetal circulation. Distribution into cerebrospinal fluid (CSF) is variable; sulfadiazine achieves concentrations approximately 50% of plasma levels, making it useful in the treatment of toxoplasmic encephalitis. Sulfonamides also achieve therapeutic levels in pleural, peritoneal, synovial, and ocular fluids. Protein binding ranges from low (sulfisoxazole, ~30%) to high (sulfadiazine, ~45%; sulfamethoxazole, ~70%). The degree of protein binding influences the volume of distribution and the potential for drug interactions involving protein-binding displacement. Trimethoprim is moderately lipid-soluble, has a volume of distribution of approximately 1-2 L/kg, and achieves tissue concentrations often higher than plasma levels, particularly in the prostate, lungs, and kidneys.

Metabolism

Sulfonamides undergo extensive metabolism, primarily in the liver via N-acetylation and glucuronidation. N-acetylation is a major pathway, producing metabolites that lack antibacterial activity. The rate of acetylation is genetically determined by polymorphisms in the N-acetyltransferase 2 (NAT2) enzyme, leading to populations of “fast” and “slow” acetylators. This polymorphism can influence the plasma half-life and, theoretically, the risk of certain adverse effects like hypersensitivity, though the clinical significance is often modest. Another critical metabolic pathway is oxidation at the N⁴ position, which can yield hydroxylamines—reactive metabolites implicated in the pathogenesis of sulfonamide hypersensitivity reactions. Trimethoprim is metabolized to a lesser extent, primarily to oxide and hydroxy metabolites.

Excretion

Both sulfonamides and their metabolites, as well as trimethoprim, are eliminated predominantly by renal excretion. This occurs through a combination of glomerular filtration and tubular secretion. The solubility of sulfonamides and their acetylated metabolites in urine is pH-dependent; they are more soluble in alkaline urine. This property is clinically significant, as acidic urine can promote the crystallization of less soluble sulfonamides (e.g., sulfadiazine) in the renal tubules, leading to crystalluria and obstructive nephropathy. Trimethoprim is a weak base and its renal excretion increases with acidic urine. In renal impairment, the elimination of both sulfamethoxazole and trimethoprim is prolonged, necessitating dose adjustment to prevent accumulation and toxicity.

Half-life and Dosing Considerations

The elimination half-life dictates the dosing frequency. Sulfisoxazole has a short half-life (~6 hours), requiring administration every 4-6 hours. Sulfamethoxazole has an intermediate half-life (~10 hours), which supports twice-daily dosing when used in cotrimoxazole. Sulfadoxine has a very long half-life (7-9 days), permitting weekly dosing for malaria prophylaxis. The half-life of trimethoprim is similar to that of sulfamethoxazole (10-12 hours), making their pharmacokinetic profiles compatible for combination therapy. In cotrimoxazole, the standard dosing for systemic infections is based on the trimethoprim component: 5-10 mg TMP/kg/day (with proportional SMX), usually divided every 12 hours. For Pneumocystis jirovecii pneumonia (PJP), higher doses are used: 15-20 mg TMP/kg/day.

5. Therapeutic Uses/Clinical Applications

The spectrum of activity of sulfonamides alone includes many gram-positive and gram-negative bacteria, Chlamydia trachomatis, and some protozoa like Toxoplasma gondii. However, widespread resistance has limited their use as monotherapy. Cotrimoxazole has a broader and more reliable spectrum due to synergy and remains a first-line or important alternative agent for several conditions.

Approved Indications

• Urinary Tract Infections (UTIs): Cotrimoxazole is effective for uncomplicated cystitis and pyelonephritis caused by susceptible strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, and others. However, resistance rates among community-acquired uropathogens have increased significantly in many regions.
• Respiratory Tract Infections:
  • Pneumocystis jirovecii Pneumonia (PJP): Cotrimoxazole is the drug of choice for both prophylaxis and treatment of PJP in immunocompromised patients (e.g., HIV/AIDS, transplant recipients).
  • Acute Exacerbations of Chronic Bronchitis: Used when caused by susceptible Haemophilus influenzae or Streptococcus pneumoniae.
  • Acute Otitis Media in Children: An alternative for penicillin-allergic patients.
• Gastrointestinal Infections:
  • Shigellosis: Cotrimoxazole is effective against susceptible Shigella species.
  • Traveler’s Diarrhea: May be used for severe cases caused by enterotoxigenic E. coli (ETEC) where resistance is not prevalent.
• Skin and Soft Tissue Infections: Used for infections caused by community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in some regions, though resistance is emerging.
• Systemic Bacterial Infections:
  • Nocardiosis: Sulfonamides (often sulfadiazine) or cotrimoxazole are the cornerstone of therapy for infections caused by Nocardia species.
  • Toxoplasmosis: Pyrimethamine combined with sulfadiazine (and leucovorin) is the standard therapy for active toxoplasmosis, especially cerebral toxoplasmosis in immunocompromised hosts.
• Prophylaxis in Immunocompromised Patients: Cotrimoxazole is used for primary and secondary prophylaxis against PJP, toxoplasmosis, and other opportunistic infections in patients with HIV, hematologic malignancies, or following organ transplantation.

Off-Label and Other Uses

• Rheumatoid Arthritis and Inflammatory Bowel Disease: Sulfasalazine is a disease-modifying antirheumatic drug (DMARD) and is used in ulcerative colitis and Crohn’s disease.
• Burn Wound Prophylaxis: Topical silver sulfadiazine and mafenide are standard agents for preventing infection in second- and third-degree burns.
• Ophthalmic Infections: Sulfacetamide eye drops are used for bacterial conjunctivitis and as adjunctive therapy in trachoma.
• Malaria: Sulfadoxine-pyrimethamine is used in combination therapy for malaria in certain endemic regions, though resistance is widespread.

6. Adverse Effects

Adverse reactions to sulfonamides and cotrimoxazole are relatively common and range from mild, dose-related effects to severe, idiosyncratic reactions. The incidence of adverse effects is generally higher with cotrimoxazole than with many other broad-spectrum antibiotics.

Common Side Effects

• Gastrointestinal Disturbances: Nausea, vomiting, anorexia, and diarrhea are frequently reported. These effects are often dose-related.
• Dermatological Reactions: Maculopapular or morbilliform rashes are common, occurring in 3-5% of patients. Photosensitivity reactions may also occur.
• Central Nervous System Effects: Headache, dizziness, and fatigue can be observed.

Serious and Rare Adverse Reactions

• Hypersensitivity Reactions: These are the most concerning adverse effects and are considered idiosyncratic.
  • Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): Severe, life-threatening mucocutaneous blistering and exfoliation. The risk is significantly higher in HIV-infected patients receiving high-dose therapy for PJP.
  • Drug Rash with Eosinophilia and Systemic Symptoms (DRESS): Presents with rash, fever, lymphadenopathy, and internal organ involvement (hepatitis, nephritis).
  • Serum Sickness-Like Reactions: Fever, arthralgias, and urticaria.

  These reactions are thought to be mediated by reactive oxidative metabolites (hydroxylamines) that act as haptens, triggering an immune response.

• Hematologic Toxicity:
  • Megaloblastic Anemia, Leukopenia, Thrombocytopenia: Trimethoprim can induce mild, reversible suppression of hematopoiesis by inhibiting human DHFR to a minor degree. This effect is potentiated in patients with pre-existing folate deficiency (e.g., malnutrition, alcoholism, pregnancy).
  • Hemolytic Anemia: May occur in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to oxidative stress on red blood cells.
  • Aplastic Anemia and Agranulocytosis: Rare but severe idiosyncratic reactions.
• Renal Toxicity:
  • Crystalluria: Primarily associated with older, less soluble sulfonamides like sulfadiazine, especially with high doses, low fluid intake, or acidic urine. Can lead to obstructive uropathy and acute kidney injury.
  • Interstitial Nephritis: An allergic inflammation of the renal interstitium, which can cause acute kidney injury.
• Hepatotoxicity: Hepatitis, ranging from mild transaminase elevation to fulminant hepatic necrosis, can occur as part of a hypersensitivity syndrome.
• Electrolyte and Metabolic Disturbances:
  • Hyperkalemia: Trimethoprim has a structure similar to amiloride and can inhibit epithelial sodium channels (ENaC) in the distal nephron, reducing potassium excretion. This is a particular concern in patients with renal impairment, diabetes, or those on concomitant potassium-sparing drugs or ACE inhibitors.
  • Hyponatremia: Has been reported, possibly due to a syndrome of inappropriate antidiuretic hormone secretion (SIADH)-like effect.
  • Metabolic Acidosis: A specific risk with topical mafenide acetate, which is absorbed and acts as a carbonic anhydrase inhibitor.

Black Box Warnings

Official labeling for cotrimoxazole carries boxed warnings concerning severe dermatologic reactions (SJS, TEN), fulminant hepatic necrosis, hematologic toxicity (agranulocytosis, aplastic anemia), and the increased risk of death in elderly patients concurrently receiving diuretics, particularly for the treatment of Pneumocystis jirovecii pneumonia. The latter warning is associated with severe hyperkalemia and sudden death in this population.

7. Drug Interactions

Sulfonamides and trimethoprim participate in several clinically significant pharmacokinetic and pharmacodynamic drug interactions.

Major Pharmacokinetic Interactions

• Warfarin: Sulfonamides can displace warfarin from plasma albumin, potentially increasing the free fraction and anticoagulant effect. Furthermore, they may inhibit the metabolism of warfarin (S-enantiomer via CYP2C9). Close monitoring of the International Normalized Ratio (INR) is mandatory.
• Sulfonylureas: Similar protein-binding displacement can enhance the hypoglycemic effect of sulfonylurea drugs (e.g., glyburide, glipizide).
• Methotrexate: Both sulfonamides and trimethoprim can displace methotrexate from protein-binding sites. More importantly, trimethoprim inhibits the renal tubular secretion of methotrexate and, by inhibiting folate metabolism, can exacerbate methotrexate’s hematologic and mucosal toxicity. This combination should be avoided.
• Phenytoin: Sulfonamides may inhibit the metabolism of phenytoin, leading to increased plasma levels and potential toxicity.
• Cyclosporine: Cotrimoxazole may reduce cyclosporine metabolism, increasing its blood levels and the risk of nephrotoxicity.

Major Pharmacodynamic Interactions

• Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Potassium-Sparing Diuretics: Concomitant use with trimethoprim significantly increases the risk of severe hyperkalemia due to additive effects on reducing renal potassium excretion.
• Thiazide Diuretics in the Elderly: As noted in the black box warning, this combination for the treatment of PJP is associated with an increased risk of thrombocytopenia and death, possibly related to hyperkalemia.
• Other Folate Antagonists: Drugs like pyrimethamine, trimethoprim, and methotrexate can have additive effects in causing folate deficiency and megaloblastic changes.
• Bone Marrow Suppressants: Additive myelosuppression can occur with other drugs causing bone marrow suppression (e.g., zidovudine, ganciclovir, chemotherapy).

Contraindications

• History of severe hypersensitivity to any sulfonamide (e.g., SJS, TEN, DRESS). Cross-reactivity between antibacterial sulfonamides and non-antibiotic sulfonamides (e.g., thiazide diuretics, sulfonylureas, furosemide) is low but may occur; caution is advised.
• Documented megaloblastic anemia due to folate deficiency.
• Marked hepatic or renal impairment where the risks outweigh benefits.
• Pregnancy at term and during the nursing period, due to the risk of kernicterus in the newborn (see Special Considerations).
• Infants less than 2 months of age, due to immature hepatic metabolism and increased risk of kernicterus.

8. Special Considerations

Use in Pregnancy and Lactation

Pregnancy (Category C/D): Sulfonamides cross the placenta. While not considered major teratogens, their use in pregnancy requires careful risk-benefit assessment. Use during the first trimester is generally avoided when possible. Use at term is contraindicated because sulfonamides can displace bilirubin from albumin-binding sites in the fetus and newborn, potentially increasing the risk of kernicterus (bilirubin encephalopathy). Trimethoprim is a folate antagonist, and theoretical concerns exist regarding its use in the first trimester due to potential interference with neural tube development. Folinic acid supplementation may be considered. Cotrimoxazole is often used for PJP prophylaxis in pregnant women with HIV, where the benefits outweigh the risks.

Lactation: Sulfonamides and trimethoprim are excreted into breast milk. While concentrations are low, there is a potential risk of kernicterus in jaundiced, ill, or premature infants, and of diarrhea or rash in the nursing infant. The American Academy of Pediatrics considers sulfisoxazole compatible with breastfeeding but suggests caution with long-acting sulfonamides. Use in a healthy, full-term infant is often considered acceptable, but alternatives may be preferred.

Pediatric Considerations

Sulfonamides are contraindicated in infants under 2 months of age due to the risk of kernicterus. In older children, dosing is based on weight or body surface area. Cotrimoxazole is commonly used for otitis media, UTIs, and PJP prophylaxis in immunocompromised children. Liquid formulations are available. The risk of SJS/TEN may be lower in children than in adults, but monitoring for rash remains essential.

Geriatric Considerations

Elderly patients often have age-related declines in renal function, increasing the risk of drug accumulation and toxicity (e.g., hyperkalemia, hematologic suppression). Dose adjustment based on creatinine clearance is crucial. The black box warning regarding concomitant use with diuretics, particularly thiazides, underscores the need for extreme caution in this population. Increased vigilance for electrolyte disturbances, renal function, and adverse dermatologic reactions is required.

Renal Impairment

Both sulfamethoxazole and trimethoprim are renally excreted. In renal impairment (creatinine clearance < 30 mL/min), the half-lives of both components are prolonged, leading to accumulation. Dose adjustment is mandatory to prevent toxicity. High-dose therapy for PJP is particularly hazardous in renal failure. Hemodialysis removes significant amounts of both drugs; therefore, a supplemental dose is usually given after each dialysis session. Monitoring of serum potassium, creatinine, and blood counts is essential.

Hepatic Impairment

Sulfonamides are metabolized in the liver. In severe hepatic disease, metabolism may be impaired, potentially leading to increased drug levels and a higher risk of toxicity, including hepatitis. Use with caution, and monitoring of liver function tests is advisable. Patients with pre-existing liver disease may be at increased risk for severe hypersensitivity reactions.

Patients with HIV/AIDS

This population has a very high incidence of adverse reactions to cotrimoxazole, especially dermatologic (rash, SJS/TEN) and hematologic toxicity, particularly when receiving high-dose treatment for PJP. Despite this, it remains the drug of choice due to its efficacy. Desensitization protocols are often successfully employed for patients who develop non-life-threatening rashes. Prophylactic use at lower doses is generally well-tolerated.

9. Summary/Key Points

• Sulfonamides are synthetic bacteriostatic antibiotics that competitively inhibit dihydropteroate synthase (DHPS), blocking bacterial folate synthesis.
• Cotrimoxazole (trimethoprim-sulfamethoxazole) produces a sequential, synergistic blockade of the folate pathway (DHPS and DHFR), often resulting in bactericidal activity and a reduced potential for resistance.
• Key pharmacokinetic features include good oral absorption, widespread tissue distribution (including CSF for some agents), hepatic metabolism (acetylation, oxidation), and renal excretion. Urine solubility is pH-dependent.
• Major clinical uses include urinary tract infections, Pneumocystis jirovecii pneumonia (prophylaxis and treatment), nocardiosis, toxoplasmosis (in combination), and certain respiratory and gastrointestinal infections.
• Adverse effects are common and can be severe. These include hypersensitivity reactions (SJS, TEN, DRESS), hematologic toxicity (megaloblastic anemia, leukopenia), hyperkalemia (trimethoprim), renal crystalluria, and hepatotoxicity.
• Significant drug interactions exist with warfarin, sulfonylureas, methotrexate, ACE inhibitors, and potassium-sparing diuretics, primarily due to protein-binding displacement, metabolic inhibition, or additive pharmacodynamic effects.
• Special population considerations: Contraindicated in infants <2 months and at term in pregnancy due to kernicterus risk. Dose adjustment is essential in renal impairment. Caution is required in the elderly, patients with HIV, and those with hepatic dysfunction or G6PD deficiency.

Clinical Pearls

• Maintain adequate hydration and consider urine alkalinization with high-dose sulfadiazine therapy to prevent crystalluria.
• Monitor serum potassium regularly, especially in patients on concomitant RAAS inhibitors, in the elderly, or in those with renal impairment receiving cotrimoxazole.
• A non-blanching, palpable purpuric rash, especially on the lower extremities, may indicate leukocytoclastic vasculitis, a rare but serious adverse reaction.
• For patients with HIV and a history of non-severe rash to cotrimoxazole, a formal desensitization protocol is a viable strategy to enable its use for essential PJP prophylaxis.
• The fixed 1:5 (TMP:SMX) ratio in cotrimoxazole is designed for systemic infections. For some specific pathogens or in certain tissues, the optimal synergistic ratio may differ, but the fixed combination remains clinically effective.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.